Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 4/20 | 0.53 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890981 | 0.86 | DPYD (0.50) | DPYDATAD2GAAMAPTALDH1A1 | |
| SCHEMBL1050748 | 0.83 | DPYD (0.47) | DPYDATAD2GAAMAPTALDH1A1 | |
| SCHEMBL8509899 | 0.82 | DPYD (0.38) | DPYDATAD2 | |
| SCHEMBL8508879 | 0.82 | KMT2A (0.41) | DPYD | |
| SCHEMBL2001029 | 0.81 | DPYD (0.53) | DPYDATAD2GAAMAPTALDH1A1 | |
| SCHEMBL887830 | 0.81 | DPYD (0.58) | DPYDATAD2GAAMAPTALDH1A1 | |
| SCHEMBL16585678 | 0.80 | GPR84 (0.46) | DPYDATAD2MAPTALDH1A1TSHR | |
| SCHEMBL887754 | 0.79 | DPYD (0.50) | DPYDATAD2GAAMAPTALDH1A1 | |
| SCHEMBL13296 | 0.79 | DPYD (0.59) | DPYDATAD2GAAMAPTALDH1A1 | |
| SCHEMBL16586721 | 0.77 | GPR84 (0.43) | DPYDMAPTLMNATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511125-B2 | Pyrimidine derivatives for labeled binding partners | CARLSBAD (US) | 2009-03-31 | — | — | US | claimed |
| US-RE39324-E1 | Pyrimidine derivatives and oligonucleotides containing same | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | claimed |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2005-01-27 | — | — | US | claimed |
| EP-1027364-B1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 2004-12-08 | — | — | EP | claimed |
| US-6800743-B2 | FOR USE AS LABELS IN DIAGNOSTIC ASSAYS AND IN ENHANCING BINDING TO COMPLEMENTARY BASES | ISIS PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | claimed |
| US-20030176677-A1 | Pyrimidine derivatives for labeled binding partners | IONIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | claimed |
| US-20030072712-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2003-04-17 | — | — | US | claimed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | claimed |
| US-6414127-B1 | INCREASED AFFINITY TO COMPLEMENTARY OLIGONUCLEOTIDES; DNA SEQUENCING; MEDICAL DIAGNOSIS; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | claimed |
| US-6380368-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-04-30 | — | — | US | claimed |
| JP-2001522860-A | — | — | 2001-11-20 | — | — | JP | claimed |
| EP-1027364-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-16 | — | — | EP | claimed |
| US-6028183-A | Pyrimidine derivatives and oligonucleotides containing same | GILEAD SCIENCES, INC. (US) | 2000-02-22 | — | — | US | claimed |
| WO-1999024452-A9 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 1999-08-12 | — | — | WO | claimed |
| WO-1999024452-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | claimed |
| US-5817781-A | ENZYME INHIBITORS; INCREASED PENETRATION OF CELLS; DEACTIVATEPROTEIN SYNTHESIS, RNA, DNA | GILEAD SCIENCES, INC. (US) | 1998-10-06 | — | — | US | claimed |
| CN-106566855-B | Nucleic acid amplification using reversibly modified oligonucleotides | 苏州新海生物科技股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-106566855-A | Nucleic acid amplification using reversibly modified oligonucleotide | 毕万里 | 2017-04-19 | — | — | CN | disclosed |
| WO-1996001841-A1 | CATIONIC LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | GILEAD SCIENCES, INC. (US) | 1996-01-25 | — | — | WO | disclosed |
| WO-1995029930-A2 | IMPROVED METHOD FOR OLIGONUCLEOTIDE ANALOG SYNTHESIS | GILEAD SCIENCES, INC. (US) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072712-A1 | Pyrimidine derivatives for labeled binding partners | DDB1, RRBP1, PRPF31 | DPYD 8/4885ATAD2 1520/4885GAA 4189/4885 |
| US-20030176677-A1 | Pyrimidine derivatives for labeled binding partners | DDB1, RRBP1, PRPF31 | DPYD 8/4885ATAD2 1520/4885GAA 4189/4885 |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | RBBP4, DDB1, DPYD | DPYD 3/4885ATAD2 1536/4885GAA 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.